IGFBP7 Binds to the IGF-1 Receptor and Blocks Its Activation by Insulin-Like Growth Factors

@article{Evdokimova2012IGFBP7BT,
  title={IGFBP7 Binds to the IGF-1 Receptor and Blocks Its Activation by Insulin-Like Growth Factors},
  author={Valentina Evdokimova and Cristina E. Tognon and Tania Benatar and Wenyi Yang and Konstantin Krutikov and Michael N. Pollak and Poul H. Sorensen and Arun K. Seth},
  journal={Science Signaling},
  year={2012},
  volume={5},
  pages={ra92 - ra92}
}
By inactivating the insulin-like growth factor receptor, IGFBP7 suppresses growth and promotes cell death. Deadly Receptor Blockade When bound to insulin-like growth factor 1 or 2 (IGF-1/2), the IGF-1 receptor (IGF1R) promotes protein synthesis, cell growth, and survival. One mechanism by which the family of IGF-binding proteins (IGFBPs) interferes with IGF1R activation is by binding to IGF-1/2. Evdokimova et al. showed that, unlike other IGFBPs, IGFBP7 attenuated activation of IGF1R in various… 
Physiological IGFBP7 levels prolong IGF1R activation in acute lymphoblastic leukemia.
TLDR
Preclinical data demonstrate that IGFBP7 is a valid target for antibody based therapeutic interventions in ALL by promoting the perdurance of IGF1R at the cell surface, prolonging insulin/IGFs stimulation.
Disorders of IGFs and IGF-1R signaling pathways
Insulin-like growth factor-binding protein 7 (IGFBP7): Novel, independent marker of cardiometabolic diseases?
TLDR
IGFBP7 could be useful in predicting the presence of atherosclerotic lesions in coronary vessels, although its concentration does not reflect a degree of coronary artery disease (CAD) advancement and it cannot be used as a marker of acute ischemia.
Insulin-Like Growth Factor System in Cancer: Novel Targeted Therapies
TLDR
The emerging view that blocking IGF via IGFBP is a better option than blocking IGF receptors is discussed, which can lead to the development of novel cancer therapies.
Insulin Growth Factor Binding Protein 7 (IGFBP7)-Related Cancer and IGFBP3 and IGFBP7 Crosstalk
TLDR
An objective of this review is to present a comprehensive overview of the relationship between IGFBP7 and cancer, as well as highlighting IGFBP3 crosstalk with IGFBP 7 reported in recent studies.
Insulin-like growth factor binding protein-related protein 1 and cancer.
IGFBP7 Deletion Promotes Hepatocellular Carcinoma.
TLDR
It is reported that Igfbp7-deficient mice exhibit constitutively active IGF signaling, presenting with proinflammatory and immunosuppressive microenvironments and spontaneous liver and lung tumors occurring with increased incidence in carcinogen-treated subjects.
Insulin-Like Growth Factor (IGF) Pathway Targeting in Cancer: Role of the IGF Axis and Opportunities for Future Combination Studies
TLDR
The preclinical and clinical experience with IGF-targeted therapies to-date are reviewed, and the rationale for future combination approaches as a means to overcome treatment resistance is discussed.
IGFBP7 is associated to prognosis and could suppress cell survival in cholangiocarcinoma
TLDR
It is found that high expression of IGFBP7 correlated to a better overall survival in CCA patients, which implicates that IGF BP7 might become a prospective benchmark for CCA diagnosis and therapy.
...
...

References

SHOWING 1-10 OF 69 REFERENCES
Inhibition of Insulin Receptor Activation by Insulin-like Growth Factor Binding Proteins*
TLDR
It is demonstrated that IGFBP-7/mac25, a newly identified member of the IGFBP superfamily that binds IGFs specifically with low affinity is a high-affinity insulin binding protein.
Insulin-like growth factor (IGF) binding protein-3 inhibits type 1 IGF receptor activation independently of its IGF binding affinity.
TLDR
The results provide the first demonstration that IGFBP-3 can specifically modulate the IGF-I signaling pathway independently of its IGF- I-binding ability and reveal a regulatory mechanism specific to the type 1 IGF receptor, with no effect on insulin receptor activation.
Cellular actions of the insulin-like growth factor binding proteins.
TLDR
In addition to their roles in IGF transport, the six IGF-binding proteins (IGFBPs) regulate cell activity in various ways and manipulation of IGFBP-regulated pathways is speculated to offer therapeutic opportunities in cancer and other diseases.
A Kinase-Independent Role for Unoccupied Insulin and IGF-1 Receptors in the Control of Apoptosis
TLDR
IR and IGF1R have bidirectional roles in the control of cell survival and can be viewed as dependence receptors, a family of receptors that mediate trophic signals when bound by ligand, and signals permissive for apoptosis in the absence of ligand.
Insulin-like growth factor (IGF) binding protein-3 interacts with the type 1 IGF receptor, reducing the affinity of the receptor for its ligand: an alternative mechanism in the regulation of IGF action.
TLDR
The present results provide the first evidence that IGFBP-3 may inhibit IGF binding to IGFR-1, and hence limit IGF action via a cellular mechanism that is different from the extracellular mechanism of sequestration.
Insulin-Like Growth Factor (IGF) Binding Protein-3 Inhibits Type 1 IGF Receptor Activation Independently of Its IGF Binding Affinity** This work was supported by the Institut National de la Santé et de la Recherche Médicale and the University of Paris VI.
TLDR
The effects of IGFBP-3 on the initial steps in the IGF signaling pathway are investigated, finding that it modulates IGF-I binding to its receptor via a different mechanism possibly involving conformational alteration of the receptor.
Essential roles of IGFBP-3 and IGFBP-rP1 in breast cancer.
Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin.
TLDR
The data suggest that specific siRNA targeting of IGF1R alone in breast cancer increases insulin sensitivity and reduces the likelihood of malignant phenotype regulated by this growth factor system.
Small molecule inhibitors of the IGF-1R/IR axis for the treatment of cancer
TLDR
The clinical success for IGF-1R/IR inhibitors may ultimately be dependent upon the ability to correctly administer these agents to the right niche patient subpopulation using single agent therapy, when appropriate, or using the right combination therapy.
...
...